AZN Stock Report - AstraZeneca ADR

AstraZeneca plc (AZN) is a multinational pharmaceutical company headquartered in Cambridge, United Kingdom. It is one of the largest pharmaceutical companies in the world and is focused on the discovery, development, and commercialization of prescription drugs in several therapeutic areas including oncology, cardiovascular, metabolic, respiratory, immunology, and neuroscience. AstraZeneca has a broad portfolio of marketed products and an extensive pipeline of drugs in development, including several potential blockbuster drugs.

AstraZeneca's most well-known drug is probably the cholesterol-lowering medication Crestor (rosuvastatin), which generated billions of dollars in annual sales before losing patent protection in 2016. Other notable products in its portfolio include the antiplatelet drug Brilinta (ticagrelor), the diabetes drug Farxiga (dapagliflozin), and the asthma drug Symbicort (budesonide/formoterol).

AstraZeneca has also been heavily involved in the development of COVID-19 vaccines. In collaboration with the University of Oxford, AstraZeneca developed a viral vector-based COVID-19 vaccine known as AZD1222, which has been authorized for emergency use in many countries. AstraZeneca has also entered into agreements with several other companies and organizations to supply the vaccine globally.

Stock Sector: Drugs: Manufacturers - Major